STARTAR: ADT + apalutamide + RT + docetaxel for PSA-recurrent prostate cancer following RP

STARTAR: AR inhibition + ADT + apalutamide + RT + docetaxel for salvage in PSA recurrent PC after RPПодробнее

STARTAR: ADT with apalutamide, radiation therapy and docetaxel in prostate cancerПодробнее

Optimizing outcomes in PSA recurrent prostate cancerПодробнее

Dr. Renee Brady-Nicholls - Using PSA Dynamics to Optimize Docetaxel Scheduling in Prostate CancerПодробнее

STARTAR: one-year follow-up resultsПодробнее

Recurrent Prostate Cancer,Rising PSA, Apalutamide,Abiraterone Acetate,Lupron,Degarelix,EnzalutamideПодробнее

Addition of docetaxel to initial hormone therapy improves survival in prostate cancerПодробнее

APF in prostate cancer patients following radical prostatectomy: what happens next?Подробнее

Docetaxel in Non-metastatic Prostate CancerПодробнее

Clinical Implications of New Data on Apalutamide ADT in Castrate-Sensitive Prostate CancerПодробнее

ARASENS: the addition of darolutamide to ADT and docetaxel for the treatment of mHSPCПодробнее

UpFrontPSMA trial: 177Lu-PSMA-617 and docetaxel in mHNPCПодробнее

Role of the addition of docetaxel to ADT in mHSPCПодробнее

CHAARTED TrialПодробнее

ADT plus docetaxel or bisphosphonates in hormone sensitive prostate cancer: Systemic reviewПодробнее

States of prostate cancer following treatment (#4)Подробнее

STAMPEDE: Docetaxel and zoledronic acid (Results for patients)Подробнее

Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate CancerПодробнее

Dr. Michael S. Cookson: Taxotere + Prostate CancerПодробнее